|2. Switch to a different TNFi biologic over switching to an IL-12/23i biologic (PICO 27)|Low (72, 73, 99, 100)|
|Conditional recommendation based on low-quality evidence; may consider an IL-12/23i if the patient had a primary TNFi biologic efficacy failure or a TNFi biologicâ€“associated serious adverse effect or prefers less frequent drug administration.| |
|3. Switch to a different TNFi biologic over switching to abatacept (PICO 70)|Low (72, 73, 103, 104)|